Skip to main content
SpringerLink
Log in

Efalizumab

Dauertherapie der Psoriasis

Efalizumab

Long-term treatment of psoriasis

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Efalizumab ist ein humanisierter monoklonaler CD11a-Antikörper. Er hemmt die T-Zell-Migration und -Aktivierung, 2 wesentliche Schritte in der Immunpathogenese der Psoriasis. Klinische Studien haben nachgewiesen, dass Efalizumab in der Behandlung der chronischen Plaquepsoriasis wirksam und sicher ist. Etwa 30% der Patienten erreichen innerhalb von 12 Wochen eine PASI-Verbesserung von ≥75% mit weiterer klinischer Besserung bei fortgesetzter Therapie. Efalizumab wird damit zu einer wichtigen Option für die Langzeittherapie der chronischen Plaquepsoriasis.

Abstract

Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of ≥75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Bauer RJ, Dedrick RL, White ML et al. (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokin Biopharm 27:397–420

    Article  Google Scholar 

  2. Coffey GP, Stefanich E, Palmieri S et al. (2004) In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 310:896–904

    Article  PubMed  Google Scholar 

  3. Dedrick RL, Walicke P, Garovoy M (2002) Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 9:181–186

    Article  PubMed  Google Scholar 

  4. Gottlieb A, Krueger JG, Bright R et al. (2000) Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Ac Dermatol 42:428–435

    Article  Google Scholar 

  5. Gottlieb AB, Gordon KB, Lebwohl MG et al. (2004) Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 3:614–624

    PubMed  Google Scholar 

  6. Gottlieb AB, Krueger JG, Wittkowski K et al. (2002) Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138:591–600

    Article  PubMed  Google Scholar 

  7. Jullien D, Prinz JC, Langley RG et al. (2004) T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 208:297–306

    Article  PubMed  Google Scholar 

  8. Leonardi CL (2004) Efalizumab in the treatment of psoriasis. Dermatol Ther 17:393–400

    Article  PubMed  Google Scholar 

  9. Leonardi CL, Papp KA, Gordon KB et al. (2005) Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Ac Dermatol 52:425–433

    Article  Google Scholar 

  10. Long A, Mitchell S, Kashanin D et al. (2004) A multidisciplinary approach to the study of T cell migration. Ann N Y Acad Sci 1028:313–319

    Article  PubMed  Google Scholar 

  11. Menter A, Craig L, Bos JD, Papp KA (2005) Longt-term management of plaque psoriasis with continuous efalizumab therapy. JAAD (im Druck)

  12. Menter A, Gordon K, Carey W et al. (2005) Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141:31–38

    Article  PubMed  Google Scholar 

  13. Menter A, Kosinski M, Bresnahan BW et al. (2004) Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3:27–38

    PubMed  Google Scholar 

  14. Papp K, Bissonnette R, Krueger JG et al. (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Ac Dermatol 45:665–674

    Article  Google Scholar 

  15. Prinz JC (2003) The role of T cells in psoriasis. J Eur Ac Dermatol 17:257–270

    Article  Google Scholar 

  16. Sun YN, Lu JF, Joshi A et al. (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45:486–476

    Google Scholar 

  17. Vugmeyster Y, Kikuchi T, Lowes MA et al. (2004) Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113:38–46

    Article  PubMed  Google Scholar 

  18. Werther WA, Gonzalez TN, O’Connor SJ et al. (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986–4995

    PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Vormals Berater für die Firma Serono, verschiedene Vorträge zum Thema Efalizumab auf firmengesponsorten Veranstaltungen.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München

    J. C. Prinz

  2. Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München, Frauenlobstraße 9–11, 80337 , München

    J. C. Prinz

Authors
  1. J. C. Prinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. C. Prinz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prinz, J.C. Efalizumab. Hautarzt 56, 812–818 (2005). https://doi.org/10.1007/s00105-005-1003-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-005-1003-9

Schlüsselwörter

Keywords

Search

Navigation